Public Meeting on Prescription Drug User Fee Act (PDUFA) Reauthorization Panel 2 – Patient Perspectives

MARC BOUTIN
CHIEF EXECUTIVE OFFICER

NATIONAL HEALTH COUNCIL







Eczema







Help Us Solve The Cruel Mystery

FOUNDATION OF AMERICA









American Diabetes Association_®



Society of America









The LAM Foundation

A BREATH OF HOPE







American Kidney Fund

















MYASTHENIA GRAVIS













Polycystic Kidney Disease















American Foundation for Suicide Prevention











American Cancer

Society®















































cancer









Other NHC Members Include:

- Providers
- Researchers
- Family Caregivers
- Biopharmaceutical
- Device
- Diagnostic
- Generic Drug
- Payers





PDUFA VI

- Enhanced Benefit-Risk Framework
- Patient-Engagement Guidances
- Enhancing RWE
- Biomarkers and Surrogate Endpoints
- Combination of Product Review
- Rare Disease Drug Development
- FDA Hiring and Retention






PDUFA VII

- Digital Clinical Trials
- RWE
- Knowledge
 Management System
- Increasing FDA Staff Capacity
- Patient-Centered Core
 Outcome Sets






Core Outcome Sets



Patient-Centered Core Outcome Sets



What is the Goal? What is Needed?

	Goals	Needs
•	Patient centricity as the core	 Get on the same page: Standardize terms, methods, approaches (but not overly
•	COSs serving as a foundation for a wide range of health care activities	prescriptive)
	ResearchClinical trials/drug developmentCare provision	 Collaboration: Multi-stakeholder, multi- disciplinary
	Quality measurementReal-world evidencePolicyValue-based	 Flexibility: Allow and support innovation and advancement in measurement and methods
	payment/contracts/agreementsOther	 Infrastructure: Convene stakeholders to determine infrastructure needs

Thank you!

Marc Boutin
Chief Executive Officer
mboutin@nhcouncil.org

